Patents by Inventor Muneo Nonomura
Muneo Nonomura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9265730Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: GrantFiled: February 28, 2014Date of Patent: February 23, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
-
Patent number: 9186411Abstract: The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.Type: GrantFiled: July 27, 2009Date of Patent: November 17, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuhiro Hiraishi, Muneo Nonomura
-
Patent number: 9011926Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.Type: GrantFiled: September 17, 2014Date of Patent: April 21, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Naoki Nagahara, Naoki Asakawa, Muneo Nonomura
-
Publication number: 20150072015Abstract: In a production process of granules containing a biologically active substance, variation in the elation profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent fox a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 more, the variation in the elution profile of the biologically active substance from the granules is reduced.Type: ApplicationFiled: September 17, 2014Publication date: March 12, 2015Inventors: Naoki NAGAHARA, Naoki ASAKAWA, Muneo NONOMURA
-
Patent number: 8927016Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.Type: GrantFiled: November 23, 2010Date of Patent: January 6, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Hisayoshi Shimizu, Muneo Nonomura, Tomomichi Futo, Kei Mukai
-
Patent number: 8871273Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.Type: GrantFiled: February 24, 2006Date of Patent: October 28, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Naoki Nagahara, Naoki Asakawa, Muneo Nonomura
-
Publication number: 20140205670Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: ApplicationFiled: February 28, 2014Publication date: July 24, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Muneo NONOMURA, Hiroki ITO, Hideo HASHIMOTO, Tadashi URAI
-
Patent number: 8697094Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: GrantFiled: October 15, 2003Date of Patent: April 15, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
-
Patent number: 8697097Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: GrantFiled: June 23, 2010Date of Patent: April 15, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
-
Publication number: 20130261156Abstract: The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.Type: ApplicationFiled: May 29, 2013Publication date: October 3, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasuhiro Hiraishi, Muneo Nonomura
-
Publication number: 20110124687Abstract: The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.Type: ApplicationFiled: July 27, 2009Publication date: May 26, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Yasuhiro Hiraishi, Muneo Nonomura
-
Publication number: 20110070311Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Inventors: Hisayoshi Shimizu, Muneo Nonomura, Tomomichi Futo, Kei Mukai
-
Publication number: 20110020410Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: ApplicationFiled: June 23, 2010Publication date: January 27, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
-
Publication number: 20100016382Abstract: The present invention provides a solid pharmaceutical composition superior in the stability and dissolution property, wherein the drug dissolution property of a solid dosage form containing a fat and oil-like substance having a low melting point is improved. The present invention provides a solid pharmaceutical composition containing an active ingredient, a fat and oil-like substance having a low melting point and a low viscosity binder, and a method of improving dissolution of an active ingredient from a solid pharmaceutical composition containing the active ingredient and a fat and oil-like substance having a low melting point, which includes using a low viscosity binder.Type: ApplicationFiled: August 9, 2007Publication date: January 21, 2010Inventors: Yukihiro Nomura, Muneo Nonomura
-
Publication number: 20080138427Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.Type: ApplicationFiled: February 24, 2006Publication date: June 12, 2008Applicant: TAKEDA PHARMACEUTICAL COMPANYInventors: Naoki Nagahara, Naoki Asakawa, Muneo Nonomura
-
Publication number: 20070141137Abstract: A capsule in which an unstable active ingredient has been stabilized is obtained by lowering the moisture content of a solid preparation (granules, subtilis, tablets, etc.) containing a chemical unstable to moisture such as an imidazole PPI compound by drying or the like, and then filling in a capsule comprising a water-soluble polysaccharide such as pullulan as the main component or a PEG-containing gelatin capsule. For the further stabilization, the capsule per se may be dried. The capsule preparation thus obtained is a stable capsule preparation with the use of a capsule being stable at a low moisture content which contains a chemical unstable to moisture such as an imidazole compound.Type: ApplicationFiled: March 3, 2005Publication date: June 21, 2007Inventors: Naoki Nagahara, Hiroki Ito, Muneo Nonomura
-
Publication number: 20060057195Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.Type: ApplicationFiled: October 15, 2003Publication date: March 16, 2006Applicant: Takeda Pharmaceutical Company LimitedInventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
-
Publication number: 20050118202Abstract: The present invention aims at stabilizing a solid composition containing a nitrogenous fused-heterocycle compound unstable to oxygen to provide a stable pharmaceutical preparation. The stabilization can be attained by keeping the equilibrium moisture content at 10% or above and/or adding ascorbic acid or a salt thereof, by preliminarily applying a film coating free from light blocking agents, or by applying one or more packaging selected from among oxygen-barrier packaging, inert gas replacement packaging, vacuum packaging and sealing packaging with an oxygen absorber.Type: ApplicationFiled: December 18, 2002Publication date: June 2, 2005Inventors: Akio Yamashita, Naoki Hirashima, Muneo Nonomura
-
Publication number: 20050100604Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.Type: ApplicationFiled: December 2, 2004Publication date: May 12, 2005Inventors: Hisayoshi Shimizu, Muneo Nonomura, Tomomichi Futo, Kei Mukai
-
Patent number: 6083916Abstract: A drug comprising either a peptide having the LH-RH action or an LH-RH antagonist is carried on an intrauterine contraceptive device (IUD) so as to be able to provide controlled release. Once the IUD is put in the uterus, the carried drug is gradually released over such a prolonged period of treatment time as, for example, several months to be continuously absorbed through the uterus mucosa or the vagina mucosa. This construction makes it possible to reduce the patient's pain and such a troublesomeness as frequent drug administration and continuously administer a necessary drug over a prolonged period of time while taking a contraceptive measures.Type: GrantFiled: March 30, 1998Date of Patent: July 4, 2000Assignee: Takeda Chemical Industries, Ltd.Inventors: Muneo Nonomura, Tomomichi Futo, Hisayoshi Shimizu